FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2810579527> ?p ?o ?g. }

• W2810579527 endingPage "256" @default.
• W2810579527 startingPage "248" @default.
• W2810579527 abstract "Several ongoing phase 2 trials are evaluating new neoadjuvant therapy regimens in patients with muscle-invasive bladder cancer (MIBC). The 1-yr recurrence-free survival (RFS) after radical cystectomy (RC), with or without perioperative chemotherapy, can be used to model statistical assumptions and interpret outcomes from these studies. To provide a benchmark for predicting 1-yr RFS in patients with cT2–4N0 MIBC. We identified 950 patients with clinical stage T2–4N0 MIBC undergoing RC at 27 centers between 1990 and 2016. We assessed 1-yr RFS rates for patients managed with no perioperative chemotherapy, neoadjuvant chemotherapy (NAC), adjuvant chemotherapy (AC), or NAC followed by AC. Cox regression analyses tested for 1-yr postsurgical RFS predictors. A Cox-based nomogram was developed to estimate 1-yr RFS and its accuracy was assessed in terms of Harrell's c-index, a calibration plot, and decision curve analysis. We report 1-yr RFS rates across the nomogram tertiles. The 1-yr RFS rates were 67.9% (95% confidence interval [CI] 64–72) after no perioperative chemotherapy, 76.9% (95% CI 72–83%) after NAC, 77.8% (95% CI 71–85%) after AC, and 57% (95% CI 37–87) after NAC + AC. On multivariable analysis, positive surgical margins (p = 0.002), pT stage (p < 0.0001), and pN stage (p<.0001) were significantly associated with RFS, while NAC was not (p = 0.6). The model including all these factors yielded a c-index of 0.76 (95% CI 0.72-0.79), good calibration, and a high net benefit. The 1-yr RFS rates across nomogram tertiles were 90.5% (95% CI 87–94%), 73.4% (95% CI 68–79%), and 51.1% (95% CI 45–58%), respectively. The results lack external validation. Benchmark 1-yr RFS estimates for phase 2 design of new neoadjuvant trials are proposed and can be used for statistical assumptions, pending external validation. Our prognostic model predicting 1-yr survival free from recurrence of bladder cancer after radical cystectomy, with or without standard chemotherapy, could provide an improvement to the quality of phase 2 clinical trial designs and interpretation of their results." @default.
• W2810579527 created "2018-07-10" @default.
• W2810579527 creator A5004985848 @default.
• W2810579527 creator A5018275141 @default.
• W2810579527 creator A5031550729 @default.
• W2810579527 creator A5032422193 @default.
• W2810579527 creator A5043616693 @default.
• W2810579527 creator A5044972820 @default.
• W2810579527 creator A5045869380 @default.
• W2810579527 creator A5050435057 @default.
• W2810579527 creator A5061623935 @default.
• W2810579527 creator A5073593424 @default.
• W2810579527 creator A5074756323 @default.
• W2810579527 creator A5080507578 @default.
• W2810579527 creator A5081296401 @default.
• W2810579527 creator A5083331837 @default.
• W2810579527 creator A5084909001 @default.
• W2810579527 creator A5088518431 @default.
• W2810579527 date "2019-05-01" @default.
• W2810579527 modified "2023-10-16" @default.
• W2810579527 title "Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2–4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials" @default.
• W2810579527 cites W1964037817 @default.
• W2810579527 cites W1972027031 @default.
• W2810579527 cites W1989399572 @default.
• W2810579527 cites W2023722883 @default.
• W2810579527 cites W2032197080 @default.
• W2810579527 cites W2045030989 @default.
• W2810579527 cites W2051762085 @default.
• W2810579527 cites W2073175347 @default.
• W2810579527 cites W2078191480 @default.
• W2810579527 cites W2102596980 @default.
• W2810579527 cites W2103561213 @default.
• W2810579527 cites W2103725052 @default.
• W2810579527 cites W2135640630 @default.
• W2810579527 cites W2137616140 @default.
• W2810579527 cites W2141663748 @default.
• W2810579527 cites W2151278059 @default.
• W2810579527 cites W2462649057 @default.
• W2810579527 cites W2518787149 @default.
• W2810579527 cites W2550294854 @default.
• W2810579527 cites W2619249519 @default.
• W2810579527 cites W2738200477 @default.
• W2810579527 cites W2771637939 @default.
• W2810579527 cites W2772360708 @default.
• W2810579527 cites W2799698221 @default.
• W2810579527 cites W2885963062 @default.
• W2810579527 cites W65610977 @default.
• W2810579527 doi "https://doi.org/10.1016/j.euo.2018.08.009" @default.
• W2810579527 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7552889" @default.
• W2810579527 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31200838" @default.
• W2810579527 hasPublicationYear "2019" @default.
• W2810579527 type Work @default.
• W2810579527 sameAs 2810579527 @default.
• W2810579527 citedByCount "10" @default.
• W2810579527 countsByYear W28105795272019 @default.
• W2810579527 countsByYear W28105795272020 @default.
• W2810579527 countsByYear W28105795272021 @default.
• W2810579527 countsByYear W28105795272022 @default.
• W2810579527 crossrefType "journal-article" @default.
• W2810579527 hasAuthorship W2810579527A5004985848 @default.
• W2810579527 hasAuthorship W2810579527A5018275141 @default.
• W2810579527 hasAuthorship W2810579527A5031550729 @default.
• W2810579527 hasAuthorship W2810579527A5032422193 @default.
• W2810579527 hasAuthorship W2810579527A5043616693 @default.
• W2810579527 hasAuthorship W2810579527A5044972820 @default.
• W2810579527 hasAuthorship W2810579527A5045869380 @default.
• W2810579527 hasAuthorship W2810579527A5050435057 @default.
• W2810579527 hasAuthorship W2810579527A5061623935 @default.
• W2810579527 hasAuthorship W2810579527A5073593424 @default.
• W2810579527 hasAuthorship W2810579527A5074756323 @default.
• W2810579527 hasAuthorship W2810579527A5080507578 @default.
• W2810579527 hasAuthorship W2810579527A5081296401 @default.
• W2810579527 hasAuthorship W2810579527A5083331837 @default.
• W2810579527 hasAuthorship W2810579527A5084909001 @default.
• W2810579527 hasAuthorship W2810579527A5088518431 @default.
• W2810579527 hasBestOaLocation W28105795272 @default.
• W2810579527 hasConcept C121608353 @default.
• W2810579527 hasConcept C126322002 @default.
• W2810579527 hasConcept C126894567 @default.
• W2810579527 hasConcept C141071460 @default.
• W2810579527 hasConcept C143998085 @default.
• W2810579527 hasConcept C146357865 @default.
• W2810579527 hasConcept C151730666 @default.
• W2810579527 hasConcept C2775910329 @default.
• W2810579527 hasConcept C2776694085 @default.
• W2810579527 hasConcept C2778292576 @default.
• W2810579527 hasConcept C2780352672 @default.
• W2810579527 hasConcept C31174226 @default.
• W2810579527 hasConcept C34626388 @default.
• W2810579527 hasConcept C44249647 @default.
• W2810579527 hasConcept C50382708 @default.
• W2810579527 hasConcept C530470458 @default.
• W2810579527 hasConcept C535046627 @default.
• W2810579527 hasConcept C71924100 @default.
• W2810579527 hasConcept C86803240 @default.
• W2810579527 hasConceptScore W2810579527C121608353 @default.
• W2810579527 hasConceptScore W2810579527C126322002 @default.
• W2810579527 hasConceptScore W2810579527C126894567 @default.

• next